CJRTP

Chinese Journal of Rehabilitation Theory and Practice >

2020 , Vol. 26 >Issue 6: 725 - 729

DOI: https://doi.org/10.3969/j.issn.1006-9771.2020.06.019

Effects of Sacral Nerve Root Magnetic Stimulation Combined with Solifenacin on Refractory Overactive Bladder in Women

  • Wen-jing ZHU ,
  • Jian-wei LÜ ,
  • Ting-ting LÜ ,
  • Xu SONG
Expand
  • 1. Department of Urology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
    2. Department of Urology, South Campus of Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201112, China
    3. Department of Urology, the Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

Received date: 2019-12-24

  Revised date: 2020-01-26

  Online published: 2020-06-29

Supported by

Shanghai Key Specialty Cultivation Project of Traditional Chinese Medicine(Urology);Key Discipline Construction Project of Pudong Health and Family Planning Commision of Shanghai(PWZxk2017-16)

Fold

Abstract

Objective To investigate the clinical efficacy of sacral nerve root magnetic stimulation combined with Solifenacin in women with refractory overactive bladder (OAB).Methods From January to December, 2017, 120 women with refractory OAB were randomly divided into sacral nerve root magnetic stimulation group (group A, n = 40), Solifenacin group (group B, n = 40), and combined treatment group (group C, n = 40). Before and after treatment, they were assessed with the urine diary (number of daily urination, number of nightly urination, single urine output, number of urgent urination), urodynamic index (initial urinary bladder capacity, maximum bladder capacity) and Overactive Bladder Symptom Score (OABSS).Results Two patients from group A, one from group B and one from group C were dropped out. The number of daily urination, the number of nightly urination, the single urine output, the number of urgent urination, the initial urinary bladder capacity and maximum bladder capacity, and OABSS were better in group C than in groups A and B (P < 0.05). Conclusion Sacral nerve root magnetic stimulation combined with Solifenacin is effective and better than anyone alone on women with refractory OAB.

Key words： refractory overactive bladder; sacral nerve root magnetic stimulation; Solifenacin

Cite this article

Wen-jing ZHU , Jian-wei LÜ , Ting-ting LÜ , Xu SONG . Effects of Sacral Nerve Root Magnetic Stimulation Combined with Solifenacin on Refractory Overactive Bladder in Women[J]. Chinese Journal of Rehabilitation Theory and Practice, 2020 , 26(6) : 725 -729 . DOI: 10.3969/j.issn.1006-9771.2020.06.019

References

[1] Coyne K S, Margolis M K, Kopp Z S, et al. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS study[J]. Urology, 2012, 79(1):95-101.
[2] 王驭良, 许克新, 胡浩, 等. 北京地区成年女性膀胱过度活动症流行病学调查及对患者生活质量的影响[J]. 中华泌尿外科杂志, 2010, 31(8):550-554.
[3] Hsiao S M, Lin H H. Medical treatment of female overactive bladder syndrome and treatment-related effects[J]. J Formos Med Assoc, 2018, 117(10):871-878.
[4] Malde S, Fry C, Schurch B, et al. What is the exact working mechanism of Botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity?[J]. Neurourol Urodyn, 2018, 37(S4):108-116.
[5] De Wachter S, Benson K D, Dmochowski R R, et al. 6-month results of selective bladder denervation in women with refractory overactive bladder[J]. J Urol, 2018, 5347(18):43909-43912.
[6] De Groat W C. A neurologic basis for the overactive bladder[J]. Urology, 1997, 50(6):36-52.
[7] Haferkamp A, Dorsam J, Elbadawi A. Ultrastructural diagnosis of neuropathic detrusor overactivity: validation of a common myogenic mechanism[J]. Adv Exp Med Biol, 2003, 539:281-291.
[8] Birder L, Andersson K E. Urothelial signaling[J]. Physiol Reviews, 2013, 93(2):653-680.
[9] Dagdeviren H, Cengiz H. Association between metabolic syndrome and serum nerve growth factor levels in women with overactive bladder[J]. Gynecol Obstet Invest, 2018, 83(2):140-144.
[10] Liu H T, Jiang Y H, Kuo H C. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy[J]. PLoS One, 2013, 8(10):1-5.
[11] Barker A T, Freeston I L, Jabinous R, et al. Clinical evaluation of conduction time measurements in central motor pathways using magnetic stimulation of human brain[J]. Lancet, 1986, 1(8493):1325-1326.
[12] Merton P A, Morton H B. Stimulation of the cerebral cortex in the intact human subject[J]. Nature, 1980, 285(5762):227.
[13] Bemelmans B L, Van Kerrebroeck P E, Notermans S L, et al. Motor evoked potentials from the bladder on magnetic stimulation of the cauda equina: a new technique for investigation of autonomic bladder innervations[J]. J Urol, 1992, 147(3):658-661.
[14] Yamanishi T, Yasuda K, Sakakibara R, et al. Induction of urethral closure and inhibition of bladder contraction by continuous magnetic stimulation[J]. Neurourol Urodyn, 1999, 18(5):505-510.
[15] Bycroft J A, Craggs M D, Sheriff M, et al. Does magnetic stimulation of sacral nerve roots cause contraction or suppression of the bladder?[J]. Neurourol Urodyn, 2004, 23(3):241-245.
[16] Khedr E M, Alkady E A, El-Hammady D H, et al. Repetitive lumbosacral nerve magnetic stimulation improves bladder dysfunction due to lumbosacral nerve injury:a pilot randomized controlled study[J]. Neurorehabil Neural Repair, 2011, 25(6):570-576.
[17] Takahashi S, Ki tamura T. Overactive bladder: magnetic versus electrical stimulation[J]. Curropin Obstet Gynecol, 2003, 15(5):429-433.
[18] Nazir J, Kelleher C, Aballéa S, et al. Comparative efficacy and tolerability of solifenacin 5?mg/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis[J]. Neurourol Urodyn, 2018, 37(3):986-996.
[19] Hakimi Z, Kelleher C, Aballéa S, et al. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK[J]. J Mark Access Health Policy, 2018, 6(1):1-7.
[20] Tanaka Y, Tanuma Y, Masumori N. Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder[J]. Int J Urol, 2016, 23(10):866-872.
[21] Kosier J H, Combest W, Newton M. Solifenacin succinate (VESIcare): overactive bladder therapy[J]. Urol Nurs, 2006, 26(6):496-497.
Options
Outlines

/

〈 〉